The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Open accessAbstract
CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A primary limitation of GUIDE-seq is relevant to the low delivery efficiency of dsODNs into cells, which results in detection of only 30%–50% of all the DSBs (Tsai et al., 2015; Pan et al., 2022).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Off-target profiling of AsCas12a-crRNA+11 genome editing in HEK293/3272-26A>G cells18,42 showed very high specificity, as demonstrated by exclusive editing of the 3272-26A>G CFTR locus, while non-specific cleavages in the second allele, or any other genomic loci, could not be detected (Fig. 2c and Supplementary Fig. 4c).”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While cleavage at sites with perfect complementarity to the protospacer domain of the gRNA typically occurs with highest efficiency, cleavage at sites having one to several bases of mismatch with the gRNA can occur. These undesired cleavage events are called “off-target effects” (OTEs)10, and their existence should be minimized for therapeutic applications of genome editing technologies.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The GUIDE-seq procedure10 can be used to empirically identify real off-target sites in cells.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq can detect off-target sites with indel frequencies as low as 0.03% (Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq is more sensitive than the IDLV method because dsODNs integrate more efficiently and precisely into DSBs, while the integration events of IDLV is low in number and can distribute as far as 500bp away from the actual DSB sites (Tsai et al., 2015; Cromer et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“However, other publications observed a much lower validation rate (Cencic et al., 2014; Duan et al., 2014; Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicated that Cas9 could associate with genomic loci without exerting its nuclease function, deposing a major caveat in Cas9 ChIP-Seq-based off-target detection assay.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, compared to cell-based methods such as GUIDE-seq (see next section) (Tsai et al., 2015), Extru-seq exhibited much lower false negative rate (2.3% versus 29%) (Kwon et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [23]
In the citing paper
“However, silicon methods can only identify part of the off-target cleavage.48”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [48]
In the citing paper
“The major barrier of clinical use of CRISPR/Cas9 is its off-target effects [81,82,83].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citationCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Self-citationRNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,009
Gee, P., Xu, H., & Hotta, A. (2017) · Stem Cells International · doi:10.1155/2017/8765154 · Cited by 37
Gene therapy and genome editing for primary immunodeficiency diseases
Zhang, Z., Thrasher, A. J., & Zhang, F. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.07.007 · Cited by 38
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
Goff, A., Cantillon, D. M., Wildner, L. M., & Waddell, S. J. (2020) · Applied Sciences · doi:10.3390/app10134629 · Cited by 38
Oura, S., Noda, T., Morimura, N., Hitoshi, S., Nishimasu, H., Nagai, Y., Nureki, O., & Ikawa, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02304-w · Cited by 40
Cromer, M. K., Barsan, V. V., Jaeger, E. B., Wang, M., Hampton, J. P., Chen, F., Kennedy, D., Xiao, J., Khrebtukova, I., Granat, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32233-z · Cited by 39
Doerfler, A. M., Park, S. H., Assini, J. M., Youssef, A., Saxena, L., Yaseen, A. B., Giorgi, M. D., Chuecos, M. A., Hurley, A. E., Li, A., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.009 · Cited by 37
Schiml, S., Fauser, F., & Puchta, H. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-4931-1_8 · Cited by 37
CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization
Chung, S. H., Sin, T.-N., Dang, B., Ngo, T., Lo, T., Lent-Schochet, D., Meleppat, R. K., Zawadzki, R. J., & Yiu, G. (2022) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2022.04.015 · Cited by 37
Zhang, C., Li, N., Rao, L., Li, J., Liu, Q., & Tian, C. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02321-21 · Cited by 42
CRISPR-M: Predicting sgRNA off-target effect using a multi-view deep learning network
Sun, J., Guo, J. H., & Liu, J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011972 · Cited by 39
Engineering APOBEC3A deaminase for highly accurate and efficient base editing
Yang, L., Huo, Y., Wang, M., Zhang, D., Zhang, T., Wu, H., Rao, X., Meng, H., Yin, S., Mei, J., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01595-4 · Cited by 38
Assessing and engineering the IscB–ωRNA system for programmed genome editing
Yan, H., Tan, X., Zou, S., Sun, Y., Ke, A., & Tang, W. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01669-3 · Cited by 36
HBV cccDNA and Its Potential as a Therapeutic Target
Zhu, A., Liao, X., Li, S., Zhao, H., Chen, L., Xu, M., & Duan, X. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2018.00054 · Cited by 37
van den Brink, L., Grandela, C., Mummery, C. L., & Davis, R. P. (2019) · Stem Cells · doi:10.1002/stem.3110 · Cited by 36
LAMA2 Neuropathies: Human Findings and Pathomechanisms From Mouse Models
Previtali, S. C., & Zambon, A. A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00060 · Cited by 36
On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
Korablev, A. N., Lukyanchikova, V., Serova, I. A., & Баттулин, Н. Р. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103604 · Cited by 37
Wang, C., Cheng, J. K. W., Zhang, Q., Hughes, N. W., Xia, Q., Winslow, M. M., & Cong, L. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1264 · Cited by 36
mRNA and gene editing: Late breaking therapies in liver diseases
Zabaleta, N., Torella, L., Weber, N. D., & González‐Aseguinolaza, G. (2022) · Hepatology · doi:10.1002/hep.32441 · Cited by 39
Clinical genome editing to treat sickle cell disease—A brief update
Zarghamian, P., Klermund, J., & Cathomen, T. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1065377 · Cited by 39
Safety, Security, and Policy Considerations for Plant Genome Editing
Wolt, J. D. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.03.005 · Cited by 37
Joris, M., Schloesser, M., Baurain, D., Hanikenne, M., Müller, M., & Motté, P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx638 · Cited by 36
Impact of Genetic Variation on CRISPR-Cas Targeting
Canver, M. C., Joung, J. K., & Pinello, L. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0016 · Cited by 36
Self-citationThe application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Hu, X., Zhang, B., Li, X., Li, M., Wang, Y., Dan, H., Zhou, J., Wei, Y., Ge, K., Li, P., et al. (2022) · Eye · doi:10.1038/s41433-022-02169-1 · Cited by 37
Amistadi, S., Maule, G., Ciciani, M., Ensinck, M. M., Keersmaecker, L. D., Ramalho, A. S., Guidone, D., Buccirossi, M., Galietta, L. J. V., Carlon, M. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.004 · Cited by 35
Exonuclease-enhanced prime editors
Truong, D. J., Geilenkeuser, J., Wendel, S. V., Wilming, J. C. H., Armbrust, N., Binder, E. M. H., Santl, T. H., Siebenhaar, A., Gruber, C., Phlairaharn, T., et al. (2024) · Nature Methods · doi:10.1038/s41592-023-02162-w · Cited by 35
Emerging Gene Therapeutics for Epidermolysis Bullosa under Development
Bischof, J., Hierl, M., & Koller, U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042243 · Cited by 36
Cui, C., Wang, S., Wang, D., Zhao, J., Huang, B., Zhu, B., Chen, Y., Tang, H., Han, Y., Cheng, Y., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01235-1 · Cited by 35
High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges
Wade, M. R. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115587916 · Cited by 39
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma
Liu, T., Shen, J. K., Li, Z., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.030 · Cited by 30
Use of genome-editing tools to treat sickle cell disease
Tasan, I., Jain, S., & Zhao, H. (2016) · Human Genetics · doi:10.1007/s00439-016-1688-0 · Cited by 36
Sanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 38
Chung, S. H., Mollhoff, I. N., Nguyen, U. T. T., Nguyen, A. B., Stucka, N., Tieu, E., Manna, S. K., Meleppat, R. K., Zhang, P., Nguyen, E. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.006 · Cited by 35
Docking sites inside Cas9 for adenine base editing diversification and RNA off-target elimination
Li, S., Yuan, B., Cao, J., Chen, J., Chen, J., Qiu, J., Zhao, X., Wang, X., Qiu, Z., & Cheng, T. (2020) · Nature Communications · doi:10.1038/s41467-020-19730-9 · Cited by 35
Simon, D. A., Tálas, A., Kulcsár, P. I., Biczók, Z., Krausz, S. L., Várady, G., & Welker, E. (2022) · eLife · doi:10.7554/elife.69504 · Cited by 35
Precision digital mapping of endogenous and induced genomic DNA breaks by INDUCE-seq
Dobbs, F. M., van Eijk, P., Fellows, M. D., Loiacono, L., Nitsch, R., & Reed, S. H. (2022) · Nature Communications · doi:10.1038/s41467-022-31702-9 · Cited by 38
Closely related type II-C Cas9 orthologs recognize diverse PAMs
Wei, J., Hou, L., Liu, J., Wang, Z., Gao, S., Qi, T., Gao, S., Sun, S., & Wang, Y. (2022) · eLife · doi:10.7554/elife.77825 · Cited by 38
Shi, Y.-J., Duan, M., Ding, J., Wang, F.-Q., Bi, L.-L., Zhang, C.-X., Zhang, Y., Duan, J.-Y., Huang, A.-H., Lei, X., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.032 · Cited by 35
CRISPR ‐Cas9 technology and its application in haematological disorders
Zhang, H., & McCarty, N. (2016) · British Journal of Haematology · doi:10.1111/bjh.14297 · Cited by 37
Rhiel, M., Geiger, K., Andrieux, G., Rositzka, J., Boerries, M., Cathomen, T., & Cornu, T. I. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1130736 · Cited by 35
Allele-specific locus binding and genome editing by CRISPR at the p16INK4a locus
Fujita, T., Yuno, M., & Fujii, H. (2016) · Scientific Reports · doi:10.1038/srep30485 · Cited by 34
Gene therapy and gene editing strategies for hemoglobinopathies
Lidonnici, M. R., & Ferrari, G. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.12.001 · Cited by 34
Li, C., Zhou, S., Li, Y., Li, G., Ding, Y., Li, L., Liu, J., Qu, L., Sonstegard, T. S., Huang, X., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00449 · Cited by 36
Xenotransplantation: Progress Along Paths Uncertain from Models to Application
Platt, J. L., Cascalho, M., & Piedrahita, J. A. (2018) · ILAR Journal · doi:10.1093/ilar/ily015 · Cited by 34
Li, B., Ren, N., Yang, L., Liu, J., & Huang, Q. (2019) · Scientific Reports · doi:10.1038/s41598-019-55463-6 · Cited by 36
Prime Editing: Precision Genome Editing by Reverse Transcription
Yan, J., Cirincione, A., & Adamson, B. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.016 · Cited by 35
Benchmarking and integrating genome-wide CRISPR off-target detection and prediction
Yan, J., Xue, D., Chuai, G., Gao, Y., Zhang, G., & Liu, Q. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa930 · Cited by 35
Kumar, J., Char, S. N., Weiss, T. J., Liu, H., Liu, B., Yang, B., & Zhang, F. (2023) · The Plant Cell · doi:10.1093/plcell/koad139 · Cited by 35
Functional interrogation of non-coding DNA through CRISPR genome editing
Canver, M. C., Bauer, D. E., & Orkin, S. H. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.008 · Cited by 36
Split Cas9, Not Hairs − Advancing the Therapeutic Index of CRISPR Technology
Schmelas, C., & Grimm, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700432 · Cited by 35
Genome-wide mapping of genomic DNA damage: methods and implications
Amente, S., Scala, G., Majello, B., Azmoun, S., Tempest, H. G., Premi, S., & Cooke, M. S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03923-6 · Cited by 33
Shakirova, A. I., Karpov, T. E., Komarova, Y., & Lepik, K. V. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1068637 · Cited by 33
Deep sampling of gRNA in the human genome and deep-learning-informed prediction of gRNA activities
Zhang, H., Yan, J., Lu, Z., Zhou, Y., Zhang, Q., Cui, T., Li, Y., Chen, H., & Ma, L. (2023) · Cell Discovery · doi:10.1038/s41421-023-00549-9 · Cited by 35
Structure and engineering of miniature Acidibacillus sulfuroxidans Cas12f1
Wu, Z., Liu, D., Pan, D. Y., Yu, H., Shi, J. F., Ma, J., Fu, W., Wang, Z., Zheng, Z., Qu, Y., et al. (2023) · Nature Catalysis · doi:10.1038/s41929-023-00995-4 · Cited by 33
Self-citationGene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
Zeng, J., Nguyen, M. A., Liu, P., da Silva, L. F., Levesque, S., Lin, L. Y., Justus, D. G., Petri, K., Clement, K., Porter, S. N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.001 · Cited by 36
Self-citationEfficient Genome Editing in Chicken DF-1 Cells Using the CRISPR/Cas9 System
Bai, Y., He, L., Li, P., Xu, K., Shao, S., Ren, C., Liu, Z., Wei, Z., & Zhang, Z. (2016) · G3 Genes Genomes Genetics · doi:10.1534/g3.116.027706 · Cited by 33
CRISPR applications in ophthalmologic genome surgery
Cabral, T., DiCarlo, J. E., Justus, S., Sengillo, J. D., Xu, Y., & Tsang, S. H. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000359 · Cited by 33
Re-engineered RNA-Guided FokI-Nucleases for Improved Genome Editing in Human Cells
Havlicek, S., Shen, Y., Alpagu, Y., Bruntraeger, M., Zufir, N. B. M., Phuah, Z. Y., Fu, Z., Dunn, N. R., & Stanton, L. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.007 · Cited by 33
Therapeutic Gene Editing Safety and Specificity
Lux, C. T., & Scharenberg, A. M. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.05.002 · Cited by 33
Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants
Dampier, W., Sullivan, N. T., Chung, C.-H., Mell, J. C., Nonnemacher, M. R., & Wigdahl, B. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-12612-z · Cited by 33
Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing
Smith, L. J., Wright, J. B., Clark, G., Ul-Hasan, T., Jin, X., Fong, A., Chandra, M., Martin, T. S., Rubin, H. L., Knowlton, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802343115 · Cited by 33
Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9
Barkau, C. L., O’Reilly, D., Rohilla, K. J., Damha, M. J., & Gagnon, K. T. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0758 · Cited by 33
The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook
Lemus, E. H., Reyes-Gopar, H., Enríquez, J. E., & Ochoa, S. (2019) · Genes · doi:10.3390/genes10110865 · Cited by 33
Niu, G., Jin, Z., Zhang, C., He, D., Gao, X., Zou, C., Zhang, W., Ding, J., Das, B. C., Severinov, K., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102897 · Cited by 34
Revisiting CRISPR/Cas-mediated crop improvement: special focus on nutrition
Kaul, T., Sony, S. K., Verma, R., Motelb, K. F. A., Prakash, A. T., Eswaran, M., Bharti, J., Nehra, M., & Kaul, R. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00094-7 · Cited by 33
HIV-1 cure strategies: why CRISPR?
Atkins, A., Allen, A. G., Dampier, W., Haddad, E. K., Nonnemacher, M. R., & Wigdahl, B. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865302 · Cited by 33
Challenges of CRISPR-Based Gene Editing in Primary T Cells
Rezalotfi, A., Fritz, L. V., Förster, R., & Bošnjak, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031689 · Cited by 33
RAISING is a high-performance method for identifying random transgene integration sites
Wada, Y., Sato, T., Hasegawa, H., Matsudaira, T., Nao, N., Coler-Reilly, A. L. G., Tasaka, T., Yamauchi, S., Okagawa, T., Momose, H., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03467-w · Cited by 33
Zhang, Y., Li, H. Z., Nishiyama, T., McAnally, J., Sanchez‐Ortiz, E., Huang, J. H., Mammen, P. P. A., Bassel‐Duby, R., & Olson, E. N. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.024 · Cited by 34
Razzaq, H. A., Ijaz, S., Haq, I. U., & Khan, I. A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07958-1 · Cited by 33
Therapeutic gene editing of T cells to correct CTLA-4 insufficiency
Fox, T. A., Houghton, B. C., Petersone, L., Waters, E., Edner, N. M., McKenna, A. J., Preham, O., Hinze, C., Williams, C., Albuquerque, A. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5811 · Cited by 35
Ye, L., Lam, S. Z., Yang, L., Suzuki, K., Zou, Y., Lin, Q., Zhang, Y., Clark, P. R., Peng, L., & Chen, S. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01058-6 · Cited by 34
CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
Chadwick, A. C., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309326 · Cited by 33
Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications
Pyzocha, N., & Chen, S. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00800 · Cited by 33
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo”
Lareau, C. A., Clement, K., Hsu, J. Y., Pattanayak, V., Joung, J. K., Aryee, M. J., & Pinello, L. (2018) · Nature Methods · doi:10.1038/nmeth.4541 · Cited by 32
Self-citationSingle-plasmid systems based on CRISPR-Cas9 for gene editing in Lactococcus lactis
Song, X., Liu, L., Liu, X., Xiong, Z., Xie, C., Wang, S.-J., & Ai, L. (2021) · Journal of Dairy Science · doi:10.3168/jds.2020-19901 · Cited by 32
CRISPR Tools for Engineering Prokaryotic Systems: Recent Advances and New Applications
Burbano, D. A., Kiattisewee, C., Karanjia, A. V., Cardiff, R. A. L., Faulkner, I., Sugianto, W., & Carothers, J. M. (2024) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100522-114706 · Cited by 34
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
Gehrke, L., Gonçalves, V. D. R., Andrae, D., Raskó, T., Ho, P., Einsele, H., Hudecek, M., & Friedel, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413685 · Cited by 34
A genome editing primer for the hematologist
Hoban, M. D., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2016-01-678151 · Cited by 32
Artificial intelligence used in genome analysis studies
D’Agaro, E. (2018) · The EuroBiotech Journal · doi:10.2478/ebtj-2018-0012 · Cited by 33
Precise Cas9 targeting enables genomic mutation prevention
Chavez, A., Pruitt, B. W., Tuttle, M. L., Shapiro, R. S., Cecchi, R. J., Winston, J., Turczyk, B. M., Tung, M., Collins, J. J., & Church, G. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718148115 · Cited by 32
Genome-Wide Off-Target Analysis in CRISPR-Cas9 Modified Mice and Their Offspring
Yan, D., Li, H., Zhao, L., Koopman, P. A., Zhang, F., & Huang, J. X. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400503 · Cited by 35
Tarakanchikova, Y. V., Alzubi, J., Pennucci, V., Follo, M., Kochergin, B. A., Muslimov, A. R., Skovorodkin, I., Vainio, S. J., Antipina, M. N., Atkin, V. S., et al. (2019) · Small · doi:10.1002/smll.201904880 · Cited by 33
Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review
Ebrahimi, V., & Hashemi, A. (2020) · Gene · doi:10.1016/j.gene.2020.144813 · Cited by 32
CRISPR-Cas systems: Challenges and future prospects
Gohil, N., Bhattacharjee, G., Lam, N. L., Perli, S. D., & Singh, V. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.008 · Cited by 33
Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing
Aquino‐Jarquín, G. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.08.002 · Cited by 34
Regulatory Considerations for Clinical Trial Applications with CRISPR-Based Medicinal Products
Anliker, B., Childs, L. H., Rau, J., Renner, M., Schüle, S., Schuessler‐Lenz, M., & Sebe, A. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0148 · Cited by 33
Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared with SpCas9 in Genome Editing
Yang, Z.-X., Fu, Y.-W., Zhao, J.-J., Zhang, F., Li, S.-A., Zhao, M., Wen, W., Zhang, L., Cheng, T., Zhang, J., et al. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.12.003 · Cited by 32
Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies
Nguyen, Q., Lim, K. R. Q., & Yokota, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030733 · Cited by 33
CRISPR off-targets: a question of context
Haeussler, M. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09497-1 · Cited by 33
Evolutionary Biology and Gene Editing of Cat Allergen, Fel d 1
Brackett, N. F., Davis, B. W., Adli, M., Pomés, A., & Chapman, M. D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0101 · Cited by 31
Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo”
Kim, S., Park, J., Kim, D., Kim, K., Bae, S., Schlesner, M., & Kim, J. (2018) · Nature Methods · doi:10.1038/nmeth.4554 · Cited by 31
PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells
Hiramoto, T., Kashiwakura, Y., Hayakawa, M., Baatartsogt, N., Kamoshita, N., Abe, T., Inaba, H., Nishimasu, H., Uosaki, H., Hanazono, Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00286-w · Cited by 31
Targeted genome editing in polyploids: lessons from Brassica
Ahmad, N., Fatima, S., Mehmood, M. A., Zaman, Q. U., Atif, R. M., Zhou, W., Rahman, M., & Gill, R. A. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1152468 · Cited by 31
Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment
Li, M., Chen, F., Yang, Q., Tang, Q., Xiao, Z., Tong, X., Zhang, Y., Lei, L., & Li, S. (2024) · Biomaterials Research · doi:10.34133/bmr.0023 · Cited by 32
Zhang, T., Tan, S., Tang, N., Li, Y., Zhang, C., Sun, J., Guo, Y., Gao, H., Cai, Y., Sun, W. H., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.007 · Cited by 32
A versatile CRISPR/Cas9 system off-target prediction tool using language model
Du, W., Zhao, L., Diao, K., Zheng, Y., Yang, Q., Zhu, Z., Zhu, X., & Tang, D. (2025) · Communications Biology · doi:10.1038/s42003-025-08275-6 · Cited by 38
Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing
Yang, H., Crosby, M., Walker, A., Wei, D. H., Leiker, K., & Weitao, T. (2017) · Journal of Cancer · doi:10.7150/jca.22554 · Cited by 32
Illuminating the genome-wide activity of genome editors for safe and effective therapeutics
Cheng, Y., & Tsai, S. Q. (2018) · Genome biology · doi:10.1186/s13059-018-1610-2 · Cited by 32
Self-citationZhang, Y., Long, Y., Yin, R., & Kwoh, C. K. (2020) · IEEE Access · doi:10.1109/access.2020.2989454 · Cited by 31
Metadata
- Authors
- Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Tsai, Shengdar Q
- Joung, J Keith
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2014-12-16
- Volume
- 33
- Issue
- 2
- Pages
- 187-197
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4320685
- OpenAlex
- W2003797386
- Cited by
- 2,268
- References
- 39
- Citations by year
- 2026: 189 · 2025: 211 · 2024: 196 · 2023: 191 · 2022: 208 · 2021: 211 · 2020: 231 · 2019: 186 · 2018: 187 · 2017: 177 · 2016: 172 · 2015: 105 · 2014: 1
- FWCI
- 62.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040, F32GM105189)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063070)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- GUIDE-seq, CRISPR-Cas nucleases, off-target cleavage, DNA double-strand breaks, genome-wide characterization, genome editing safety
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Cell Line, Humans, Oligodeoxyribonucleotides, Genome, Human, RNA Editing, DNA Breaks, Double-Stranded, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
